Abstract:The Philadelphia chromosome is formed by a balanced, reciprocal translocation that pairs sequences from BCR on Chromosome 22 with sequences from ABL on Chromosome 9, resulting in the production of the constitutively active tyrosine kinase (TK) BCR-ABL. Depending on the location of the breakpoint within BCR, three different sizes of BCR-ABL may form, each associated with distinct clinical sequelae. Previous studies identified a functional domain within the BCR sequences preserved by the more-indolent forms of BCR-ABL (i.e., p210 and p230) that demonstrates a constitutive Rho guanine nucleotide exchange factor (RhoGEF) activity. Using the structurally derived S509A mutation, which does not affect TK activity but abrogates RhoGEF signaling, we, subsequently, showed that this feature regulates leukemia progression in mice. The RhoGEF domain was recently reported to contain two missense mutations (F547L and T654K) in a chronic myelogenous leukemia (CML) blast crisis (BC) patient, suggesting that it may play a role in human disease as well. To evaluate the clinical significance of this region, we, therefore, examined p210 BCR-ABL constructs containing these clinically derived RhoGEF mutations (CDRMs), both in isolation and in combination, using a murine bone marrow transplant (mBMT) model of CML. The mutations did not destabilize p210 BCR-ABL expression or TK activity but decreased RhoGEF signaling. Relative to mice transplanted with wild-type (WT) p210 BCR-ABL, those that received the CDRMs exhibited an earlier onset of disease, frequently developing previously unseen dermatologic involvement or myeloid sarcomas, but demonstrated significantly increased survival in an additive manner [Fig. 1]. While mice transplanted with WT p210 BCR-ABL exhibited neutrophilia that progresses to a less-differentiated phenotype at death, disease in the CDRM mice was characterized by eosinophilia and monocytosis with no maturation arrest. The most likely cause of death in mice transplanted with WT p210 BCR-ABL is widespread hematogenous involvement of the lungs resulting in acute respiratory distress. In contrast, mice receiving the CDRMs demonstrated pulmonary involvement which was limited to the bronchovascular bundles or subpleural space. This is consistent with a switch to lymphatogenous spread, likely secondary to skewed differentiation, and it implies an alternate cause(s) of death. To help determine the mechanism responsible for the observed differences in differentiation and maturation arrest, we next studied the CDRMs in vitro using the 32Dcl3 murine myeloid precursor cell line. A growing body of evidence suggests that the DNA damage response can affect lineage restriction in myeloid cells; it is also well-established that the accumulation of DNA damage is necessary for progression to BC. Accordingly, the CDRMs were associated with the restoration of p53 activation and the G1/S cell cycle checkpoint relative to WT p210 BCR-ABL. This suggests that the RhoGEF domain may be responsible for the suppression of the DNA damage response. Because the mBMT phenotype associated with the S509A mutation was distinct from that of the CDRMs, it may indicate that this capability is mediated by some functionality yet to be described. Importantly, the CDRMs were also associated with increased Src family kinase activity, which is thought to be a major mechanism of BCR-ABL-independent TK inhibitor resistance and minimal residual disease. Collectively, these results suggest that the BCR-ABL RhoGEF domain can influence disease progression and response to treatment in human leukemia. Disclosures No relevant conflicts of interest to declare.

Localization of BCR-ABL to F-actin Regulates Cell Adhesion but Does Not Attenuate CML Development

Bcr-Abl Induces Abnormal Cytoskeleton Remodeling, Β1 Integrin Clustering and Increased Cell Adhesion to Fibronectin Through the Abl Interactor 1 Pathway

Examination of Clinically-Derived p210 BCR/ABL Rhogef Mutations in a Murine Bone Marrow Transplantation Model of CML

The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia

Effects of Bcr/abl Fusion Gene on Expression of Β1 Integrin and L-selectin in Mouse Chronic Myeloid Leukemia Cells

Polarized Distribution of Bcr-Abl in Migrating Myeloid Cells and Co-Localization of Bcr-Abl and Its Target Proteins

Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML

The Coiled-Coil Domain And Tyr177 Of Bcr Are Required To Induce A Murine Chronic Myelogenous Leukemia-Like Disease By Bcr/Abl

The N-terminal Domain of the Non-Receptor Tyrosine Kinase ABL Confers Protein Instability and Suppresses Tumorigenesis

Abi1 Gene Silencing by Short Hairpin RNA Impairs Bcr-Abl-induced Cell Adhesion and Migration in Vitro and Leukemogenesis in Vivo

[Beta1 Integrin Dysfunction in Adult Chronic Myeloid Leukemia Bone Marrow Cells]

SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia

C-Abl is Involved in the F-Actin Assembly Triggered by L-Selectin Crosslinking

C-Cbl is Not Required for Leukemia Induction by Bcr-Abl in Mice

The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia

Bcr-Abl with an SH3 Deletion Retains the Ability to Induce a Myeloproliferative Disease in Mice, Yet C-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy.

Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2

Inhibition of Class Ii Phosphoinositide 3-Kinase Gamma Expression by P185(Bcr-Abl) Contributes to Impaired Chemotaxis and Aberrant Homing of Leukemic Cells

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

Bcr-Abl Has a Greater Intrinsic Capacity Than V-Abl to Induce the Neoplastic Expansion of Myeloid Cells

BCR/ABL Activates Rap1 and B-Raf to Stimulate the MEK/Erk Signaling Pathway in Hematopoietic Cells.